Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kezar Life Sciences Inc
(NQ:
KZR
)
0.6287
-0.0013 (-0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kezar Life Sciences Inc
< Previous
1
2
3
Next >
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 06, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 13, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 07, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
November 14, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
November 09, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
November 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
October 14, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 06, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
October 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
September 29, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 02, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
September 01, 2022
From
Kezar Life Science
Via
Business Wire
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
July 07, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 06, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
June 27, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
May 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 15, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
March 17, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Appoints Courtney Wallace to its Board of Directors
December 10, 2021
From
Kezar Life Sciences
Via
Business Wire
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
November 15, 2021
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
November 11, 2021
From
Kezar Life Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.